APA (7th ed.) Citation

Lee, C., Lee, J. B., Park, S. J., Che, J., Kwon, W. S., Kim, H. S., . . . Rha, S. Y. (2024). Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: A multicenter phase Ib/II study. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 27(1), 118-130. https://doi.org/10.1007/s10120-023-01435-9

Chicago Style (17th ed.) Citation

Lee, Choong-kun, et al. "Second-line Chemoimmunotherapy with Nivolumab and Paclitaxel in Immune-related Biomarker-enriched Advanced Gastric Cancer: A Multicenter Phase Ib/II Study." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 27, no. 1 (2024): 118-130. https://doi.org/10.1007/s10120-023-01435-9.

MLA (9th ed.) Citation

Lee, Choong-kun, et al. "Second-line Chemoimmunotherapy with Nivolumab and Paclitaxel in Immune-related Biomarker-enriched Advanced Gastric Cancer: A Multicenter Phase Ib/II Study." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 27, no. 1, 2024, pp. 118-130, https://doi.org/10.1007/s10120-023-01435-9.